Executive Medical Director - Physician -early Clinical Development, Immunology

Eli Lilly Eli Lilly · Pharma · US, Boston MA, US: Indianapolis IN Corporate Center, US: San Diego CA Lilly Biotechnology Center, US, San Francisco CA

Executive Medical Director for Early Clinical Development in Immunology at Eli Lilly, focusing on developing transformational medicines for autoimmune and inflammatory diseases. This role bridges discovery science and clinical application, requiring strong matrix leadership and strategic portfolio management.

What you'd actually do

  1. Collaborate with discovery, translational medicine, and clinical teams to develop and refine therapeutic hypotheses for autoimmune and inflammatory diseases
  2. In collaboration with stakeholders, design early clinical studies that efficiently test therapeutic hypotheses
  3. Lead early clinical strategy in cross-functional teams through matrix influence, aligning diverse stakeholders around common objectives
  4. Establish and maintain relationships with key opinion leaders and scientific experts in autoimmunity and inflammation
  5. Partner with regulatory colleagues on IND strategy, FDA interactions, and global development planning

Skills

Required

  • Medical Doctor or Doctor of Osteopathy
  • Board eligible or certified in Rheumatology, Dermatology, Gastroenterology, Allergy/Immunology, or related specialty
  • Clinical translational leadership
  • Matrix leadership
  • Strategic portfolio management
  • Clinical study design
  • Biomarker strategy
  • Regulatory affairs
  • GCP, FDA, ICH guidelines compliance
  • Scientific expertise
  • Cross-functional team leadership
  • Key opinion leader engagement
  • Scientific conferences
  • Business development support
  • IND strategy

Nice to have

  • Emerging industry leader
  • Executive presence
  • Inspire high-performing teams
  • Mentor and develop junior team members
  • Culture-shaping leader

What the JD emphasized

  • enterprise influence
  • strategic leader
  • matrix leadership
  • cross-functional partners
  • enterprise visibility
  • cross-functional teams
  • matrix influence
  • scientific rigor
  • clinical feasibility
  • commercial potential
  • transformational potential
  • early clinical development
  • early clinical studies
  • early decision-making
  • early-stage immunology assets